US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US7612196B2
(en)
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
AU2003295600A1
(en)
|
2002-11-14 |
2004-06-15 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
US7781575B2
(en)
|
2002-11-14 |
2010-08-24 |
Dharmacon, Inc. |
siRNA targeting tumor protein 53 (p53)
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
AU2003267347A1
(en)
*
|
2003-09-10 |
2005-03-29 |
Galapagos Genomics N.V. |
Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell
|
AU2003300239A1
(en)
*
|
2003-12-29 |
2005-07-21 |
Galapagos Genomics N.V. |
Modulators of bone homeostasis identified in a high-throughput screen
|
WO2005071079A1
(en)
*
|
2004-01-21 |
2005-08-04 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Inhibitors of mammalian hdac 11 useful for treating hdac 11 mediated disorders
|
GB0403600D0
(en)
*
|
2004-02-18 |
2004-03-24 |
Trinity College Dublin |
Methods and reagents for treating disease
|
EP2520652B1
(en)
|
2004-04-09 |
2015-06-10 |
Genecare Research Institute Co., Ltd |
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
|
DK1745295T3
(en)
|
2004-04-20 |
2011-01-31 |
Galapagos Nv |
Methods, compositions and compound assays to inhibit the production of amyloid beta protein
|
MXPA06012162A
(en)
|
2004-04-27 |
2007-03-30 |
Galapagos Nv |
Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts.
|
JP2008502355A
(en)
|
2004-06-14 |
2008-01-31 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
Identification methods and compounds useful in the treatment of degenerative and inflammatory diseases
|
EP2360474B1
(en)
|
2004-06-21 |
2013-07-24 |
Galapagos N.V. |
Methods and means for treatment of osteoarthritis
|
US8673268B2
(en)
|
2004-10-15 |
2014-03-18 |
Galapagos N.V. |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
US7485468B2
(en)
|
2004-10-15 |
2009-02-03 |
Galapagos Bv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
TWI386225B
(en)
*
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
Rnai inhibition of ctgf for treatment of ocular disorders
|
WO2006108584A2
(en)
*
|
2005-04-15 |
2006-10-19 |
Cenix Bioscience Gmbh |
Human marker genes and agents for cardiovascular disorders and artherosclerosis
|
EP1924294A4
(en)
*
|
2005-05-24 |
2010-11-03 |
Isis Pharmaceuticals Inc |
Compositions and their uses directed to ptpru
|
US8795976B2
(en)
|
2005-07-29 |
2014-08-05 |
Oncotherapy Science, Inc. |
Gene and polypeptide relating to breast cancer
|
KR20070101610A
(en)
*
|
2006-04-11 |
2007-10-17 |
주식회사 바이오인프라 |
Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent
|
TW201336514A
(en)
*
|
2006-04-13 |
2013-09-16 |
Alcon Res Ltd |
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
|
WO2007121156A2
(en)
|
2006-04-13 |
2007-10-25 |
Alcon Research, Ltd |
Rnai-mediated inhibition of histamine receptor h1-related conditions
|
EP2152875A2
(en)
*
|
2007-05-02 |
2010-02-17 |
Sirna Therapeutics Inc. |
Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina)
|
US20100120895A1
(en)
*
|
2007-05-02 |
2010-05-13 |
Merck & Co., Inc. |
RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
EP2152877A2
(en)
*
|
2007-05-02 |
2010-02-17 |
Sirna Therapeutics Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CYCLIC NUCLEOTIDE TYPE 4 PHOSPHODIESTERASE ( PDE4B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20100137406A1
(en)
*
|
2007-05-02 |
2010-06-03 |
Merck & Co., Inc |
RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
AR066984A1
(en)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA)
|
US8637257B2
(en)
|
2007-06-20 |
2014-01-28 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
|
RU2010111120A
(en)
*
|
2007-08-24 |
2011-09-27 |
Онкотерапи Сайенс, Инк. (Jp) |
EB13, DLX5, NPTX1 AND CDKN3 AS TARGET TARGETS FOR THERAPY AND DIAGNOSTICS OF LUNG CANCER
|
AU2008323970B2
(en)
*
|
2007-11-09 |
2014-05-08 |
Isis Pharmaceuticals, Inc. |
Modulation of Factor 7 expression
|
EP2313506A1
(en)
*
|
2008-07-11 |
2011-04-27 |
Medizinische Universität Innsbruck |
Antagonists of nr2f6 for augmenting the immune response
|
ES2343292B1
(en)
*
|
2008-07-24 |
2011-06-20 |
Universidad Complutense De Madrid |
SIRNA AND SHRNA FOR THE ELABORATION OF MEDICINES AGAINST THE ELEVATED PRESSURE INTRAOCULAR.
|
EP2816113A3
(en)
|
2008-09-11 |
2015-03-25 |
Galapagos N.V. |
Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
|
JP2012517821A
(en)
|
2009-02-19 |
2012-08-09 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
Identification method and compound useful for diagnosis and treatment of diseases including inflammation
|
US20120004160A1
(en)
|
2009-02-19 |
2012-01-05 |
Glaxo Group Ltd. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
WO2010094732A1
(en)
|
2009-02-19 |
2010-08-26 |
Biofocus Dpi B.V. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
US20120004281A1
(en)
*
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US8993509B2
(en)
|
2009-03-31 |
2015-03-31 |
Robert Zimmerman |
Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
|
WO2010112569A1
(en)
|
2009-03-31 |
2010-10-07 |
Robert Zimmermann |
Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
|
EP2414829A1
(en)
|
2009-04-01 |
2012-02-08 |
Galapagos N.V. |
Methods and means for treatment of osteoarthritis
|
EP2236607A1
(en)
*
|
2009-04-02 |
2010-10-06 |
Sanofi-Aventis |
Use of inhibitors of St3Gla6 activity for modulation of adipogenesis
|
TW201102081A
(en)
|
2009-05-11 |
2011-01-16 |
Oncotherapy Science Inc |
TTK peptides and vaccines including the same
|
KR101702689B1
(en)
*
|
2009-06-16 |
2017-02-06 |
큐알엔에이, 인크. |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
WO2011105901A2
(en)
*
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
WO2011105900A2
(en)
*
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
WO2011105902A2
(en)
*
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
RU2588654C2
(en)
|
2010-06-23 |
2016-07-10 |
Курна, Инк. |
Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
|
WO2013038907A1
(en)
*
|
2011-09-14 |
2013-03-21 |
日本化薬株式会社 |
Method for inhibiting cell growth, nucleic acid molecule having rna interference effect on nek10 variant gene, and anticancer agent
|
KR20140084232A
(en)
|
2011-10-25 |
2014-07-04 |
아이시스 파마수티컬즈 인코포레이티드 |
Antisense modulation of gccr expression
|
WO2013177468A2
(en)
*
|
2012-05-24 |
2013-11-28 |
Isis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein(a) expression
|
WO2013173789A2
(en)
|
2012-05-17 |
2013-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
WO2014139884A2
(en)
|
2013-03-14 |
2014-09-18 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis
|
WO2014139883A1
(en)
|
2013-03-14 |
2014-09-18 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
|
US20160003808A1
(en)
|
2013-03-14 |
2016-01-07 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
|
PT3444350T
(en)
|
2013-07-03 |
2022-02-04 |
Dicerna Pharmaceuticals Inc |
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna
|
EP3105331B1
(en)
*
|
2014-02-11 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
WO2015171918A2
(en)
*
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
US9458464B2
(en)
|
2014-06-23 |
2016-10-04 |
The Johns Hopkins University |
Treatment of neuropathic pain
|
US10792299B2
(en)
|
2014-12-26 |
2020-10-06 |
Nitto Denko Corporation |
Methods and compositions for treating malignant tumors associated with kras mutation
|
US20180002702A1
(en)
|
2014-12-26 |
2018-01-04 |
Nitto Denko Corporation |
Methods and compositions for treating malignant tumors associated with kras mutation
|
US11045488B2
(en)
|
2014-12-26 |
2021-06-29 |
Nitto Denko Corporation |
RNA interference agents for GST-π gene modulation
|
US10264976B2
(en)
*
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
WO2016164407A2
(en)
*
|
2015-04-07 |
2016-10-13 |
Polyskope Labs |
Detection of one or more pathogens
|
AU2016259971B2
(en)
*
|
2015-05-11 |
2021-12-09 |
ProGenis Pty Ltd |
Multiple sclerosis treatment
|
CN109477106B
(en)
|
2015-07-10 |
2022-10-04 |
Ionis制药公司 |
Modulators of diacylglycerol acyltransferase 2 (DGAT 2)
|
CN105349665B
(en)
*
|
2015-11-27 |
2018-06-19 |
上海锐赛生物技术有限公司 |
Kit of colorectal cancer risk of recurrence and application thereof after assessment oxaliplatin chemotherapeutic
|
WO2017120365A1
(en)
|
2016-01-05 |
2017-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing lrrk2 expression
|
WO2017207656A1
(en)
*
|
2016-05-31 |
2017-12-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Atp6ap2 inhibition for treating or preventing a tumoural and/or proliferative disorder of the central nervous system
|
KR20200024793A
(en)
|
2017-07-06 |
2020-03-09 |
애로우헤드 파마슈티컬스 인코포레이티드 |
RNAi Agents and Methods of Inhibiting the Expression of Alpha-ENaC
|
US11564936B2
(en)
|
2017-08-10 |
2023-01-31 |
Washington University |
Compositions and methods of treatment using nicotinamide mononucleotide
|
CN108387621B
(en)
*
|
2018-01-10 |
2019-11-26 |
暨南大学 |
Cadmium ion aptamer and screen printing electrode electrochemica biological sensor
|
UY38282A
(en)
|
2018-06-27 |
2019-12-31 |
Ionis Pharmaceuticals Inc |
COMPOUNDS AND METHODS FOR REDUCING THE EXPRESSION OF LRRK2
|
CN109402117B
(en)
*
|
2018-11-07 |
2022-03-01 |
上海中医药大学附属曙光医院 |
Adeno-associated virus for silencing expression of mouse intestinal RASGRP1 and preparation method and application thereof
|
WO2020101880A1
(en)
*
|
2018-11-14 |
2020-05-22 |
Oklahoma Medical Research Foundation |
Compositions and methods of treating systemic lupus erythematosus
|
WO2020117706A1
(en)
*
|
2018-12-03 |
2020-06-11 |
Triplet Therapeutics, Inc. |
Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
|
EP4133077A1
(en)
*
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
WO2022066847A1
(en)
*
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
TW202229552A
(en)
*
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
JP2024515423A
(en)
|
2021-02-26 |
2024-04-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
|
CN113430199A
(en)
*
|
2021-06-30 |
2021-09-24 |
武汉三鹰生物技术有限公司 |
Interfering sequence of HADHA mRNA and verification method thereof
|
WO2023114989A2
(en)
*
|
2021-12-17 |
2023-06-22 |
University Of Massachusetts |
Oligonucleotides for mlh3 modulation
|
WO2023154964A1
(en)
*
|
2022-02-14 |
2023-08-17 |
Alloy Therapeutics, Inc. |
Methods and compositions for targeting efemp1
|